Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2020 | Lung ART trial updates from ESMO 2020

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, summarizes the key findings of the Lung ART trial (NCT00410683) which investigated postoperative conformal radiotherapy (PORT) in patients with completely resected non-small-cell lung cancer (NSCLC) and mediastinal N2 involvement. Treatment using adjuvant PORT was associated with a non-statistically significant 15% increase in disease-free survival (DFS). Prof. Popat discusses a potential benefit for the therapy in other patient groups. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.